Close Menu

NEW YORK – Transplant diagnostics company CareDx reported on Wednesday after the close of the market that its preliminary revenues for the first quarter of 2020 are expected to rise 47 percent year over year, despite a recent lag in testing service volumes due to the COVID-19 pandemic.

The company also withdrew its previously announced revenue guidance for full-year 2020 because of uncertainties surrounding the impact of COVID-19. Management will provide additional information during its Q1 earnings conference call.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.